A Phase 1 interventional study of Telmisartan/Amlodipine and Telmisartan/Amlodipine/HCTZ in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-30.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess drug drug interaction through pharmacokinetics investigation at steady state of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) given as three different formulations in healthy Japanese male subjects
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmisartan/Amlodipine/HCTZ fixed-dose combination
Drug: Telmisartan/Amlodipine/HCTZ
Telmisartan/Amlodipine fixed-dose combination
Drug: Telmisartan/Amlodipine
Telmisartan/HCTZ fixed-dose combination
Drug: Telmisartan/HCTZ
Drug pages: Telmisartan · Amlodipine
Telmisartan/Amlodipine fixed-dose combination
Drug pages: Telmisartan · Amlodipine · Hydrochlorothiazide
Telmisartan/Amlodipine/HCTZ fixed-dose combination
Drug pages: Telmisartan · Hydrochlorothiazide
Telmisartan/HCTZ fixed-dose combination
Maximum Measured Concentration (Cmax) at Steady State for Telmisartan
Maximum measured concentration (Cmax) of telmisartan in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration
Area Under the Plasma Concentration Curve at Steady State for Telmisartan
Area under the plasma concentration curve (AUC) of telmisartan in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h and 72h after 10 days drug administration
Maximum Measured Concentration (Cmax) at Steady State for Amlodipine
Maximum measured concentration (Cmax) of amlodipine in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration
Area Under the Plasma Concentration Curve at Steady State for Amlodipine
Area under the plasma concentration curve (AUC) of amlodipine in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h and 144h after 10 days drug administration
Maximum Measured Concentration (Cmax) at Steady State for HCTZ
Maximum measured concentration (Cmax) of HCTZ in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration
Area Under the Plasma Concentration Curve at Steady State for HCTZ
Area under the plasma concentration curve (AUC) of HCTZ in plasma at steady state over the dosing interval tau
Time frame: 15 minutes (min) before drug administration and 15min, 30min, 45min, 1 hour (h), 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 12h, 24h, 32h and 48h after 10 days drug administration
Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours
Amount of HCTZ excreted in urine over the time interval from 0 to 24 hours at steady state
Time frame: 0-6 hours (h), 6-12h and 12-24h after drug administration on day 10
An open-label, randomised, six-sequence crossover design. Each participant received three treatments each for 10 days. There was no washout period between treatments.
| Milestone | T80-A5-H12.5 / T80-H12.5 / T80-A5 | T80-H12.5 / T80-A5 / T80-A5-H12.5 | T80-A5 / T80-A5-H12.5 / T80-H12.5 | T80-A5 / T80-H12.5 / T80-A5-H12.5 | T80-A5-H12.5 / T80-A5 / T80-H12.5 | T80-H12.5 / T80-A5-H12.5 / T80-A5 |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | T80-A5-H12.5 / T80-H12.5 / T80-A5 | T80-H12.5 / T80-A5 / T80-A5-H12.5 | T80-A5 / T80-A5-H12.5 / T80-H12.5 | T80-A5 / T80-H12.5 / T80-A5-H12.5 | T80-A5-H12.5 / T80-A5 / T80-H12.5 | T80-H12.5 / T80-A5-H12.5 / T80-A5 |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 | 6 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 |
| Milestone | T80-A5-H12.5 / T80-H12.5 / T80-A5 | T80-H12.5 / T80-A5 / T80-A5-H12.5 | T80-A5 / T80-A5-H12.5 / T80-H12.5 | T80-A5 / T80-H12.5 / T80-A5-H12.5 | T80-A5-H12.5 / T80-A5 / T80-H12.5 | T80-H12.5 / T80-A5-H12.5 / T80-A5 |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 4 |
| Completed | 6 | 6 | 6 | 6 | 6 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum measured concentration (Cmax) of telmisartan in plasma at steady state over the dosing interval tau
| ng/mL | T80-A5-H12.5 | T80-A5 | T80-H12.5 |
|---|---|---|---|
| Maximum Measured Concentration (Cmax) at Steady State for Telmisartan | 970 ± 69.3 | 857 ± 70.7 | 895 ± 75.0 |
Area under the plasma concentration curve (AUC) of telmisartan in plasma at steady state over the dosing interval tau
| ng*h/mL | T80-A5-H12.5 | T80-A5 | T80-H12.5 |
|---|---|---|---|
| Area Under the Plasma Concentration Curve at Steady State for Telmisartan | 2510 ± 72.1 | 2570 ± 70.8 | 2580 ± 81.4 |
Amount of HCTZ excreted in urine over the time interval from 0 to 24 hours at steady state
| mg | T80-A5-H12.5 | T80-H12.5 |
|---|---|---|
| Amount of HCTZ Excreted in Urine at Steady State From 0 to 24 Hours | 10.4 ± 11.4 | 9.9 ± 12.2 |
Maximum measured concentration (Cmax) of amlodipine in plasma at steady state over the dosing interval tau
| ng/mL | T80-A5-H12.5 | T80-A5 |
|---|---|---|
| Maximum Measured Concentration (Cmax) at Steady State for Amlodipine | 11.8 ± 21.8 | 11.3 ± 22.3 |
Area under the plasma concentration curve (AUC) of amlodipine in plasma at steady state over the dosing interval tau
| ng*h/mL | T80-A5-H12.5 | T80-A5 |
|---|---|---|
| Area Under the Plasma Concentration Curve at Steady State for Amlodipine | 230 ± 23.4 | 223 ± 21.8 |
Maximum measured concentration (Cmax) of HCTZ in plasma at steady state over the dosing interval tau
| ng/mL | T80-A5-H12.5 | T80-H12.5 |
|---|---|---|
| Maximum Measured Concentration (Cmax) at Steady State for HCTZ | 107 ± 28.5 | 102 ± 28.0 |
Area under the plasma concentration curve (AUC) of HCTZ in plasma at steady state over the dosing interval tau
| ng*h/mL | T80-A5-H12.5 | T80-H12.5 |
|---|---|---|
| Area Under the Plasma Concentration Curve at Steady State for HCTZ | 584 ± 23.8 | 565 ± 23.4 |
Collected over 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T80-A5-H12.5 | — | 0/36 (0%) | 3/36 (8.3%) |
| T80-H12.5 | — | 0/36 (0%) | 3/36 (8.3%) |
| T80-A5 | — | 0/34 (0%) | 2/34 (5.9%) |
| All Patients | — | 0/36 (0%) | 5/36 (13.9%) |
| Event | T80-A5-H12.5 | T80-H12.5 | T80-A5 | All Patients |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 3/36 | 2/36 | 2/34 | 4/36 |
| C-reactive protein increasedInvestigations | 1/36 | 1/36 | 0/34 | 2/36 |
Treated set which included all subjects that were dispensed study drug and were documented to have taken at least one dose of study drug.
| Age, Continuous(Years) | T80-A5-H12.5 / T80-H12.5 / T80-A5 | T80-H12.5 / T80-A5 / T80-A5-H12.5 | T80-A5 / T80-A5-H12.5 / T80-H12.5 | T80-A5 / T80-H12.5 / T80-A5-H12.5 | T80-A5-H12.5 / T80-A5 / T80-H12.5 | T80-H12.5 / T80-A5-H12.5 / T80-A5 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 29.0 ± 4.9 | 27.3 ± 5.2 | 27.0 ± 4.2 | 25.8 ± 4.1 | 29.5 ± 5.1 | 29.3 ± 4.9 | 28.0 ± 4.6 |
| Sex: Female, Male(Participants) | T80-A5-H12.5 / T80-H12.5 / T80-A5 | T80-H12.5 / T80-A5 / T80-A5-H12.5 | T80-A5 / T80-A5-H12.5 / T80-H12.5 | T80-A5 / T80-H12.5 / T80-A5-H12.5 | T80-A5-H12.5 / T80-A5 / T80-H12.5 | T80-H12.5 / T80-A5-H12.5 / T80-A5 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 36 |
The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine · Hydrochlorothiazide